First Horizon Corp Has $12.67 Million Position in McKesson Corporation $MCK

Posted by Stanley Muller on Jul 10th, 2026

First Horizon Corp lessened its position in McKesson Corporation (NYSE:MCK – Free Report) by 4.6% during the first quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 14,646 shares of the company’s stock after selling 710 shares during the quarter. First Horizon Corp’s holdings in McKesson were worth $12,674,000 as of its most recent filing with the SEC.

Other hedge funds also recently made changes to their positions in the company. Norges Bank acquired a new position in McKesson during the fourth quarter worth $1,651,137,000. Swedbank AB increased its stake in McKesson by 42.2% in the 4th quarter. Swedbank AB now owns 886,283 shares of the company’s stock valued at $727,009,000 after buying an additional 263,189 shares during the last quarter. SurgoCap Partners LP boosted its stake in shares of McKesson by 68.7% during the 3rd quarter. SurgoCap Partners LP now owns 452,261 shares of the company’s stock worth $349,390,000 after buying an additional 184,106 shares during the last quarter. Robeco Institutional Asset Management B.V. increased its position in shares of McKesson by 73.7% in the fourth quarter. Robeco Institutional Asset Management B.V. now owns 432,578 shares of the company’s stock valued at $354,839,000 after acquiring an additional 183,590 shares during the last quarter. Finally, Danica Pension Livsforsikringsaktieselskab bought a new stake in McKesson during the third quarter worth about $135,352,000. 85.07% of the stock is owned by institutional investors.

Key McKesson News

Here are the key news stories impacting McKesson this week:

Positive Sentiment: McKesson’s last earnings report beat adjusted EPS estimates and management reaffirmed FY2027 adjusted EPS guidance of $43.80 to $44.60, which supports the company’s longer-term earnings outlook.
Positive Sentiment: Analyst sentiment remains generally favorable, with a moderate buy consensus and multiple firms maintaining overweight/buy ratings, suggesting Wall Street still sees upside potential.
Neutral Sentiment: McKesson recently announced its next earnings date for August 5, so investors are likely in a wait-and-see mode ahead of the next quarterly update.
Neutral Sentiment: The company also disclosed new debt tied to the planned separation of its Medical-Surgical Solutions business, a move that may improve strategic focus but also keeps attention on execution and balance-sheet changes.
Negative Sentiment: Investors are still reacting to the prior quarter’s revenue shortfall, which outweighed the EPS beat and has kept sentiment cautious around near-term growth.
Negative Sentiment: Recent leadership turnover, including the planned retirement of Chief Strategy and Business Development Officer Thomas L. Rodgers and a large CEO stock sale under a 10b5-1 plan, may be adding to concerns about insider confidence and continuity.

Insider Activity

In other news, CAO Napoleon B. Rutledge, Jr. sold 133 shares of McKesson stock in a transaction on Friday, June 5th. The stock was sold at an average price of $764.00, for a total value of $101,612.00. Following the transaction, the chief accounting officer owned 632 shares in the company, valued at approximately $482,848. This trade represents a 17.39% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Thomas L. Rodgers sold 2,388 shares of McKesson stock in a transaction dated Tuesday, May 26th. The shares were sold at an average price of $761.09, for a total value of $1,817,482.92. Following the completion of the transaction, the executive vice president owned 3,090 shares in the company, valued at approximately $2,351,768.10. This represents a 43.59% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last ninety days, insiders sold 28,748 shares of company stock valued at $22,262,035. 0.06% of the stock is owned by insiders.

McKesson Price Performance

MCK stock opened at $793.32 on Friday. The business’s fifty day moving average price is $766.72 and its two-hundred day moving average price is $838.77. The stock has a market capitalization of $92.88 billion, a price-to-earnings ratio of 20.62, a PEG ratio of 1.35 and a beta of 0.31. McKesson Corporation has a fifty-two week low of $637.00 and a fifty-two week high of $999.00.

McKesson (NYSE:MCK – Get Free Report) last released its quarterly earnings results on Thursday, May 7th. The company reported $11.69 EPS for the quarter, beating the consensus estimate of $11.56 by $0.13. McKesson had a net margin of 1.18% and a negative return on equity of 345.35%. The business had revenue of $96.30 billion for the quarter, compared to the consensus estimate of $101.35 billion. During the same period in the prior year, the company posted $10.12 earnings per share. McKesson’s revenue was up 6.0% compared to the same quarter last year. McKesson has set its FY 2027 guidance at 43.800-44.600 EPS. Research analysts expect that McKesson Corporation will post 44.28 EPS for the current year.

McKesson Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, July 1st. Investors of record on Monday, June 1st were paid a $0.82 dividend. This represents a $3.28 dividend on an annualized basis and a yield of 0.4%. The ex-dividend date of this dividend was Monday, June 1st. McKesson’s dividend payout ratio (DPR) is 8.53%.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on MCK shares. Bank of America dropped their price objective on McKesson from $1,040.00 to $1,000.00 and set a “buy” rating on the stock in a research note on Monday, April 6th. Weiss Ratings downgraded shares of McKesson from a “buy (b)” rating to a “buy (b-)” rating in a report on Tuesday. Citigroup dropped their price target on shares of McKesson from $975.00 to $945.00 and set a “buy” rating on the stock in a research report on Thursday, May 14th. Wall Street Zen cut shares of McKesson from a “buy” rating to a “hold” rating in a research note on Saturday, June 27th. Finally, Deutsche Bank Aktiengesellschaft restated a “buy” rating and set a $875.00 price objective on shares of McKesson in a research note on Friday, May 8th. Fourteen research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, McKesson currently has a consensus rating of “Moderate Buy” and a consensus price target of $960.53.

Get Our Latest Analysis on McKesson

McKesson Profile

(Free Report)

McKesson Corporation (NYSE: MCK) is a global healthcare services and distribution company that supplies pharmaceuticals, medical-surgical products and health care technology solutions. Founded in 1833 and headquartered in Irving, Texas, McKesson operates across the drug distribution and healthcare services value chain, connecting manufacturers, pharmacies, hospitals and health systems to help manage the movement of medicines and clinical supplies.

The company’s core activities include pharmaceutical wholesale distribution and logistics, specialty pharmacy services, and the provision of medical-surgical supplies to acute and non-acute care providers.